[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$gipr](/topic/$gipr) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "$GIPR Growing Market Demand🚀🚀🚀 Chinas obesity treatment market sees growing demand; dual GLP-1/GIP agonists provide new options for patients and revenue potential for pharma companies. 👉 X stocks heating upjoin the group to see the list 🔗" [X Link](https://x.com/turneraudrey40/status/1979593116920508914) [@turneraudrey40](/creator/x/turneraudrey40) 2025-10-18T16:59Z XX followers, XX engagements "$GIPR Leading in GLP-1 Market🚀🚀🚀 Tirzepatide strengthens Eli Lillys position in the GLP-1 sector offering superior weight management and metabolic benefits. 👉 Track turning-point stocks with daily trade signals in the group. 🔗" [X Link](https://x.com/LaurenKing0718/status/1979593104165638537) [@LaurenKing0718](/creator/x/LaurenKing0718) 2025-10-18T16:59Z XXX followers, XX engagements "$GIPR HRS9531 Clinical Data🚀🚀🚀 Hengruis dual GLP-1/GIP agonist shows XXXX% average weight loss at XX weeks in high-dose group with XXXX% losing XX% body weight. 👉 Missed the last XXX% runner Dont miss the nextjoin now. 🔗" [X Link](https://x.com/neonheartrock/status/1979593085475774967) [@neonheartrock](/creator/x/neonheartrock) 2025-10-18T16:59Z XXX followers, XX engagements "$GIPR Tirzepatide Approved in China🚀🚀🚀 Eli Lillys dual GLP-1/GIP agonist Tirzepatide gets approval in China for obesity marking first dual receptor therapy in the market. 👉 Share the next 10x bull stock in the group. 🔗" [X Link](https://x.com/pammys72/status/1979593075145277549) [@pammys72](/creator/x/pammys72) 2025-10-18T16:59Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$GIPR Growing Market Demand🚀🚀🚀 Chinas obesity treatment market sees growing demand; dual GLP-1/GIP agonists provide new options for patients and revenue potential for pharma companies. 👉 X stocks heating upjoin the group to see the list 🔗"
X Link @turneraudrey40 2025-10-18T16:59Z XX followers, XX engagements
"$GIPR Leading in GLP-1 Market🚀🚀🚀 Tirzepatide strengthens Eli Lillys position in the GLP-1 sector offering superior weight management and metabolic benefits. 👉 Track turning-point stocks with daily trade signals in the group. 🔗"
X Link @LaurenKing0718 2025-10-18T16:59Z XXX followers, XX engagements
"$GIPR HRS9531 Clinical Data🚀🚀🚀 Hengruis dual GLP-1/GIP agonist shows XXXX% average weight loss at XX weeks in high-dose group with XXXX% losing XX% body weight. 👉 Missed the last XXX% runner Dont miss the nextjoin now. 🔗"
X Link @neonheartrock 2025-10-18T16:59Z XXX followers, XX engagements
"$GIPR Tirzepatide Approved in China🚀🚀🚀 Eli Lillys dual GLP-1/GIP agonist Tirzepatide gets approval in China for obesity marking first dual receptor therapy in the market. 👉 Share the next 10x bull stock in the group. 🔗"
X Link @pammys72 2025-10-18T16:59Z XXX followers, XX engagements
/topic/$gipr/posts